Evidence map›Paper›PMID 39654364›Full record

ArticleESC heart failure2025

Incidence of atrial fibrillation in patients with an insertable cardiac monitor and symptomatic heart failure.

Muhammad Shahzeb Khan, Michael R Zile, Rami Kahwash, Shantanu Sarkar, Brian Van Dorn, Jodi Koehler, Noreli Franco, Bart Gerritse, Javed Butler

Abstract read
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Muhammad Shahzeb KhanBaylor Scott and White Research Institute, Dallas, Texas, USA.ORCID https://orcid.org/0000-0003-1250-6351
Michael R ZileMedical University of South Carolina, Charleston, South Carolina, USA.ORCID https://orcid.org/0000-0001-7076-221X
Rami KahwashThe Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0001-5009-2909
Shantanu SarkarMedtronic, Mounds View, Minnesota, USA.ORCID https://orcid.org/0000-0002-3613-5463
Brian Van DornMedtronic, Mounds View, Minnesota, USA.ORCID https://orcid.org/0000-0002-8685-5442
Jodi KoehlerMedtronic, Mounds View, Minnesota, USA.
Noreli FrancoMedtronic, Mounds View, Minnesota, USA.ORCID https://orcid.org/0000-0001-7264-8939
Bart GerritseMedtronic Bakken Research Center, Maastricht, Netherlands.ORCID https://orcid.org/0000-0002-3121-1367
Javed ButlerBaylor Scott and White Research Institute, Dallas, Texas, USA.ORCID https://orcid.org/0000-0001-7683-4720

Funding

Medtronic
6 · The paper itself

Abstract

aimsWe aim to evaluate the incidence of atrial fibrillation (AF) in a large real-world cohort of patients implanted with an insertable cardiac monitor (ICM) who had a clinical history of symptomatic heart failure (HF) with reduced or preserved left ventricular ejection fraction (LVEF).

methodsPatients with an ICM and a history of HF events were identified from the Optum® de-identified Electronic Health Record dataset merged with an ICM device dataset collected during 2007-2021. All ICM-detected AF episodes that were available with ≥30-s of ECG at onset were adjudicated using artificial intelligence (AI model). Episodes with AI model probability of AF ≥ 0.9 were analysed. The Kaplan-Meier incidence of AF as a function of episode duration, history of AF, and LVEF were assessed.

resultsA total of 1020 patients with ICM were identified of whom 911 had ≥180 days of follow-up and were included. According to the AI model, 358 patients had 8407 episodes of true AF. Incidence of AF at 42 months was 45.6% (44.1% vs. 46.8% in reduced vs. preserved LVEF). Incidence of new-onset AF was 23.2% (23.3% vs. 22.2% in reduced vs. preserved LVEF) in patients with no clinical history of AF. Patients with new-onset AF had a higher HF event rate compared with patients who had no clinical history of AF and did not develop AF during follow-up [OR = 2.73 (1.47-5.09); P = 0.002]. Patients with preserved LVEF had more longer duration paroxysmal AF compared with those with reduced LVEF (44.5% vs. 33.9%, P = 0.02).

conclusionsAF was observed in almost half of patients with ICM and symptomatic HF. One-fourth of the patients had new onset AF and a higher rate of HF events compared with patients without AF. AF incidence was similar in patients with preserved and reduced LVEF.

Indexed as

Atrial FibrillationElectrocardiography, AmbulatoryHeart FailureStroke VolumeVentricular Function, LeftAgedFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedRetrospective StudiesAtrial fibrillationHeart failureHFpEFHFrEFInsertable cardiac monitorPreserved and reduced LVEF

Identifiers

PMID39654364
PMCPMC12055352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.